Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study
CONCLUSION: This real-world cohort study showed that BIC/FTC/TAF could achieve good immunological and virological responses in ART-naïve patients. In addition, this study also shows good safety.PMID:38058002 | DOI:10.1080/14787210.2023.2292544 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 7, 2023 Category: Infectious Diseases Authors: Lin Gan Xiaoxin Xie Yanhua Fu Yebing Song Chunli Song Tingting Ren Hai Long Source Type: research
Tenofovir-based first-line regimen in newly diagnosed HIV-patients: An experience from a Tertiary Care Hospital in India
Conclusion: The present study highlights the importance of long-term follow-up of the patients on antiretroviral therapy. Adequate monitoring of the treatment parameters is of utmost importance. (Source: Indian Journal of Sexually Transmitted Diseases)
Source: Indian Journal of Sexually Transmitted Diseases - December 6, 2023 Category: Infectious Diseases Authors: Arkapal Bandyopadhyay Sarika Palepu Bhawna Saini Rakesh Chandra Chaurasia Rakesh Kumar Yadav Source Type: research
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial
Antiviral therapy has been reported to be associated with lower recurrence rate of hepatocellular carcinoma (HCC) for patients with hepatitis B virus (HBV) infection. While entecavir (ETV) and tenofovir disopr... (Source: Trials)
Source: Trials - December 2, 2023 Category: General Medicine Authors: Wei Peng, Mengshi Yi, Xin Qi, Weili Qi, Chuan Li and Tianfu Wen Tags: Methodology Source Type: research
RWD150 A Prescription Pattern of HIV First-Line Tenofovir Alafenamide-Based Single-Tablet Regimens: A Multi-Institutional Study in Taiwan
This study was aimed to analyze prescribing pattern of two TAF-based STRs using real-world data, including TAF/emtricitabine(FTC)/RPV and TAF/FTC/BIC. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: H.Y. Lin, K.C. Chang, H.Y. Chen Source Type: research
CO121 Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis B Undergoing Antiviral Treatments in a Real-World Setting
This study aimed to examine the prevalence of musculoskeletal and renal outcomes in patients receiving ENT, TDF, and TAF. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: H. Lee, B.K. Kim, A. Kim Source Type: research
Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients
CONCLUSION: The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.PMID:38032036 | DOI:10.1097/CM9.0000000000002939 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - November 30, 2023 Category: General Medicine Authors: Jiang Xiao Guiju Gao Yi Ding Jialu Li Chengyu Gao Qiuhua Xu Liang Wu Hongyuan Liang Liang Ni Fang Wang Yujiao Duan Di Yang Hongxin Zhao Source Type: research
Pyruvate dehydrogenase is a potential mitochondrial off-target for gentamicin based on in silico predictions and in vitro inhibition studies
In conclusion, the use of in silico methods appeared a valuable approach in predicting PDH as a mitochondrial off-target of gentamicin. Further research is required to investigate the contribution of PDH inhibition to overall renal toxicity of gentamicin.PMID:38036072 | DOI:10.1016/j.tiv.2023.105740 (Source: Toxicology in Vitro)
Source: Toxicology in Vitro - November 30, 2023 Category: Toxicology Authors: Charlotte A Hoogstraten Jan B Koenderink Carolijn E van Straaten Tom Scheer-Weijers Jan A M Smeitink Tom J J Schirris Frans G M Russel Source Type: research
Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients
CONCLUSION: The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.PMID:38032036 | DOI:10.1097/CM9.0000000000002939 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - November 30, 2023 Category: General Medicine Authors: Jiang Xiao Guiju Gao Yi Ding Jialu Li Chengyu Gao Qiuhua Xu Liang Wu Hongyuan Liang Liang Ni Fang Wang Yujiao Duan Di Yang Hongxin Zhao Source Type: research
Pyruvate dehydrogenase is a potential mitochondrial off-target for gentamicin based on in silico predictions and in vitro inhibition studies
In conclusion, the use of in silico methods appeared a valuable approach in predicting PDH as a mitochondrial off-target of gentamicin. Further research is required to investigate the contribution of PDH inhibition to overall renal toxicity of gentamicin.PMID:38036072 | DOI:10.1016/j.tiv.2023.105740 (Source: Toxicology in Vitro)
Source: Toxicology in Vitro - November 30, 2023 Category: Toxicology Authors: Charlotte A Hoogstraten Jan B Koenderink Carolijn E van Straaten Tom Scheer-Weijers Jan A M Smeitink Tom J J Schirris Frans G M Russel Source Type: research
Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
Whether different anti-hepatitis B virus (HBV) drugs have different effects on COVID-19 is controversial. We aimed to evaluate the incidence of COVID-19 in chronic hepatitis B (CHB) patients receiving anti-HBV... (Source: BMC Infectious Diseases)
Source: BMC Infectious Diseases - November 30, 2023 Category: Infectious Diseases Authors: Xingmei Liao, Yujie Fan, Chunxiu Zhong, Siru Zhao, Liangxu Guo, Wenjuan Tan, Junhua Yin and Rong Fan Tags: Research Source Type: research
Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
(Source: Therapeutics and Clinical Risk Management)
Source: Therapeutics and Clinical Risk Management - November 29, 2023 Category: Drugs & Pharmacology Tags: HIV/AIDS - Research and Palliative Care Source Type: research
Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research
Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research
Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research
